Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Drum beat until May 25th

<< Previous

Bullboard Posts

Next >>

Comment by askretkaon May 06, 2023 3:15pm

219 Views

Post# 35434764

RE:RE:RE:Drum beat until May 25th

Jimsenior That's a pretty good summary actually.

The big thing you missed was that a company with their own CAR-T has reproduced the original 7/7 mouse cures or close to it. Results are " IN LINE " with those reported in Translational Medicine article.

They are now repeating the results just to be sure.
Because CAR-T's are gene specific and each one is a bit different.

So if results repeat we will have 2 separate CAR-T s that work in solid tumors and Dr. Viles upcoming preclinical results and a strong possibility of opening up the 85% solid tumor market to CAR-T.

Cheers!!!!!!!!!!!!!!!

<< Previous

Bullboard Posts

Next >>

How a junior advances one of the largest undeveloped diamond projects